TY - JOUR
T1 - In vitro antibacterial activity of at-2266 and its therapeutic efficacy on respiratory tract infections
AU - Aonuma, Seiichi
AU - Onuma, Kikuo
AU - Watanabe, Akira
AU - Sasaki, Masako
AU - Oizumi, Kotaro
AU - Konno, Kiyoshi
AU - Nagai, Kosaku
PY - 1984/1
Y1 - 1984/1
N2 - Recently, a new oral antimicrobial agent, structurally related to nalidixic acid, was synthesized in laboratory of Dainippon Pharmaceutical Co. Ltd. in Japan. It was shown that this new agent possessed a broad antimicrobial spectrum covering gram-positive cocci and gram-negative bacilli. Minimal inhibitory concentrations (MICs) of the agent against each 20 clinical isolates of S. aureus, E. coli, K. pneumoniae, S. marcescens, E. cloacae and P. aeruginosa were determined by use of Dynatech MIC 2000 system. At a concentration of 0.78μg/ml, this agent inhibited 65, 85, 95, 90, 80 and 70% of the strains of S. aureus, E.coli, K. pneumoniae, S. marcescens, E. cloacae and P. aeruginosa, respectively. Nine patients suffering from respiratory tract infections received orally 600 mg of the drug a day. Seven showed a good response and two a fair response. No undesirable symptoms and signs due to administration of the drug were observed. No abnormality in laboratory findings was noted during and after the treatment with the drug.
AB - Recently, a new oral antimicrobial agent, structurally related to nalidixic acid, was synthesized in laboratory of Dainippon Pharmaceutical Co. Ltd. in Japan. It was shown that this new agent possessed a broad antimicrobial spectrum covering gram-positive cocci and gram-negative bacilli. Minimal inhibitory concentrations (MICs) of the agent against each 20 clinical isolates of S. aureus, E. coli, K. pneumoniae, S. marcescens, E. cloacae and P. aeruginosa were determined by use of Dynatech MIC 2000 system. At a concentration of 0.78μg/ml, this agent inhibited 65, 85, 95, 90, 80 and 70% of the strains of S. aureus, E.coli, K. pneumoniae, S. marcescens, E. cloacae and P. aeruginosa, respectively. Nine patients suffering from respiratory tract infections received orally 600 mg of the drug a day. Seven showed a good response and two a fair response. No undesirable symptoms and signs due to administration of the drug were observed. No abnormality in laboratory findings was noted during and after the treatment with the drug.
UR - http://www.scopus.com/inward/record.url?scp=0021366258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021366258&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1953.32.Supplement3_385
DO - 10.11250/chemotherapy1953.32.Supplement3_385
M3 - Article
AN - SCOPUS:0021366258
SN - 0009-3165
VL - 32
SP - 385
EP - 390
JO - CHEMOTHERAPY
JF - CHEMOTHERAPY
IS - Supplement
ER -
